Biotricity Reports Record Revenue Increase and Positive Cashflow
Biotricity Inc. (OTCQB: BTCY), a leader in the Technology-as-a-Service (TaaS) sector focused on remote cardiac monitoring, is excited to announce that it has reached a significant milestone: cashflow breakeven. This achievement comes alongside a remarkable revenue increase of 11% from the previous quarter, setting the stage for continued growth in fiscal year 2025.
Impressive Q3 Revenue Growth
The company anticipates reporting an impressive 22% growth in revenue for Q3 FY25 compared to the same period last year, aiming for total revenues of approximately $3.6 million. This equates to an 11% increase from the prior quarter, demonstrating strong momentum in Biotricity's financial performance.
Focus on Recurring Revenue and Operational Efficiency
Management remains committed to driving recurring revenue growth and increasing operational efficiencies. By focusing on these key areas, Biotricity is not only improving its gross margins but also moving closer to long-term profitability. Their objective is to maintain this upward trend, enhancing cashflow while controlling costs.
Innovative Solutions Transforming Healthcare
Dr. Waqaas Al-Siddiq, Biotricity's Founder and CEO, highlighted the company's dedication to innovating healthcare technology. He expressed pride in the continued development of the Biocore product suite, which utilizes sophisticated data analytics to enhance healthcare outcomes through rigorous research and development. This commitment positions Biotricity at the forefront of medical diagnostics and patient care, utilizing AI-driven solutions to redefine traditional practices.
Upcoming Financial Results and Call
Biotricity has scheduled a conference call for stakeholders and investors to discuss third-quarter results and future outlook. This call will take place soon, where management will provide insightful updates on the company’s performance. These results are expected to showcase all the improvements in key operating metrics, reinforcing the company's strong financial discipline.
Call details include:
- Date: Upcoming Thursday
- Time: 5:30 PM ET
- Toll-Free Number: 877-269-7751
- International Dial-In: 1-201-389-0908
Investors and Transparency
The company emphasizes transparency, offering a replay of the conference call shortly after it concludes, allowing stakeholders to access key information. Further details on financial results will also be submitted to the SEC, ensuring all investors are kept informed.
About Biotricity
Biotricity is dedicated to bridging the gap in remote healthcare management, providing innovative solutions for preventive care and chronic condition management. Their commitment to excellence in diagnostic and post-diagnostic services establishes trust between healthcare providers and patients alike. By developing comprehensive remote health monitoring solutions that cater to both medical and consumer markets, Biotricity is making significant strides towards enhancing health outcomes.
Frequently Asked Questions
What are the key financial highlights reported by Biotricity?
Biotricity is anticipating a 22% growth in revenue compared to the same quarter last year, aiming for $3.6 million in total revenue.
How does Biotricity plan to maintain its growth trajectory?
The company is concentrating on driving recurring revenues and enhancing operational efficiencies, which are essential for sustainable growth.
When will Biotricity release its full financial results?
The company plans to release its complete financial results soon, with a conference call scheduled for Thursday at 5:30 PM ET.
What innovative products is Biotricity emphasizing?
Biotricity is focusing on the Biocore product suite, utilizing data collection and AI-driven solutions to improve healthcare outcomes.
What is Biotricity's objective regarding profitability?
Biotricity's goal is to achieve profitability by continually improving cash flow and maintaining strong cost controls.
